Medical/Pharmaceuticals

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including$420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead...

2024-11-21 06:00 2424

Complete Genomics announces mpox virus amplicon sequencing panel at AMP

VANCOUVER, BC, Nov. 20, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, Calif.-based genomic sequencer manufacturer, today announced at the 2024 Association for Molecular Pathology (AMP) Annual Meeting & Expo the launch of its mpox (MPXV) virus amplicon sequencing panel, part of its sequencin...

2024-11-21 01:01 1786

GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products

PLANTATION, Fla., Nov. 21, 2024 /PRNewswire/ -- GBI Biomanufacturing (GBI), one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP)services, to include automated sterile fill and finish capabilit...

2024-11-21 01:00 1660

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preservingweight loss in Obesity LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech compan...

2024-11-20 22:00 2365

CABIO Deepens Commitment to Global Markets, Aiming to Serve International Clients and Pursue Long-Term International Partnerships

FRANKFURT, Germany, Nov. 20, 2024 /PRNewswire/ -- CABIO, a high-tech enterprise underpinned by biotechnology and listed on the Science and Technology Innovation Board (stock code: 688089), unveiled its innovative product, NeoHMOs®, at the Food Ingredients Europe event held inFrankfurt, Germany. ...

2024-11-20 21:00 1709

Head:China makes collaborative efforts in healing people with mental disorders with AI

BEIJING, Nov. 20, 2024 /PRNewswire/ -- After a long day at work, Ni Beiyue sits in front of his computer at home, eagerly immersing himself in the world of creating short videos with AI (artificial intelligence) tools. For nearly three hours, he brainstorms video content, generates mental images ...

2024-11-20 15:13 2117

SD Biosensor and the NCCD Discuss Cooperation Measures to Eradicate Infectious Diseases

* A team of officials from the National Center for Communicable Diseases, Mongolia (NCCD), had a tour around the Cheongju and Jeungpyeong Factories of SD Biosensor, aSouth Korea's global in-vitro diagnostics company, during their visit to Korea. * SD Biosensor introduced total diagnostic plat...

2024-11-20 12:44 2184

Forging New Paths: Alfasigma Group and Fangzhou Inc. Chart a Course for Internet Healthcare

SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- On November 13th, a high-level delegation from the Alfasigma Group, led by Mr. Andriy Samoylovych, Chief Commercial Officer of Global Growth Markets, and Ms.Zhou Qin, General Manager of Alfasigma China, met with Dr. Xie Fangmin, Chairman and CEO of Fangzhou...

2024-11-20 10:38 1972

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

SINGAPORE, Nov. 20, 2024 /PRNewswire/ -- Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, andEdith Cowan University Australia (ECU) today announced a new strategic partnership that aims to enhance clinical ultrasound training for healthcare professio...

2024-11-20 09:00 8881

Samsung Biologics signs manufacturing deal with European pharmaceutical company

* The company will provide manufacturing services through 2031 in deals worth overUSD 668 million * Samsung Biologics' cumulative contract value for 2024 surpasses USD 4 billion with latest deals INCHEON, South Korea, Nov. 20, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global ...

2024-11-20 07:23 2198

Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B

SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical Devices Safe...

2024-11-20 07:20 2012

Datasea Pre-Announces Full-Year Fiscal 2025 Revenue of $90 Million, Representing a Year-Over-Year Increase of 275%, with Expected Significant Gross Profit Improvement

BEIJING, Nov. 19, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-registered digital technology company focused on innovations in acoustic high-tech and 5G AI multimodal digital technologies, today pre-announced that its revenue for the fiscal year ending Jun...

2024-11-19 22:45 2698

Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson's Research Through Development of Next Generation Biomarker Assays

FREMONT, Calif., Nov. 19, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to accelerate biomarker disco...

2024-11-19 22:12 2039

Say Hello to 3.0: Datarithm Releases Latest Version of Inventory Management Solution

SYRACUSE, N.Y., Nov. 19, 2024 /PRNewswire/ -- In a landscape marked by intense competition, rising costs, and stringent regulatory requirements, independent pharmacies face an array of challenges that threaten their viability and success. Today, Datarithm® is proud to announce a solution to these...

2024-11-19 22:00 1596

Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS

NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siR...

2024-11-19 21:26 2136

Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity

* "DigiCoach program" is a pilot program by Singapore Health Promotion Board, Health2Sync, and Abbott that aims to help individuals with pre-diabetes or high BMI prevent or delay the onset of diabetes. * Participants can use a continuous glucose monitoring (CGM) device and the Health2Sync mob...

2024-11-19 21:00 2243

2024 Access to Medicine Index finds that pharma companies are missing opportunities to reach more patients in low- and middle-income countries

AMSTERDAM, Nov. 19, 2024 /PRNewswire/ -- The 2024 Access to Medicine Index finds that pharmaceutical companies are not fully leveraging thei...

2024-11-19 21:00 753

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...

2024-11-19 20:30 2240

Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA

48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to suppor...

2024-11-19 19:30 3299

Digital Medicine Society Launches Resources to Navigate Global Digital Health Regulatory Pathways

Resources will speed the expansion of digital health products worldwide, improving global patient access  BOSTON, Nov. 19, 2024 /PRNewswire/ -- Today, the Digital Medicine Society (DiMe) unveiled a suite of resources to guide industry in evaluating international regulatory pathways. These resourc...

2024-11-19 19:00 2376
1 ... 150151152153154155156 ... 646

Week's Top Stories